<?xml version="1.0" encoding="UTF-8"?>
<ref id="B26" class="ref">
 <mixed-citation publication-type="journal" class="mixed-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Schwarz</surname>
    <given-names class="given-names">U. I.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Gramatte</surname>
    <given-names class="given-names">T.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Krappweis</surname>
    <given-names class="given-names">J.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Oertel</surname>
    <given-names class="given-names">R.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Kirch</surname>
    <given-names class="given-names">W.</given-names>
   </name>
  </person-group> (
  <year class="year">2000</year>). 
  <article-title class="article-title">P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.</article-title>
  <source class="source">
   <italic class="italic">Int. J. Clin. Pharmacol. Ther.</italic>
  </source>
  <volume class="volume">38</volume>
  <fpage class="fpage">161</fpage>â€“
  <lpage class="lpage">167</lpage>. 
  <pub-id pub-id-type="doi" class="pub-id">10.5414/cpp38161</pub-id>
  <?supplied-pmid 10783825?>
  <pub-id pub-id-type="pmid" class="pub-id">10783825</pub-id>
 </mixed-citation>
</ref>
